By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Lymphoproliferative Disorders. According to news originating from Cambridge, Massachusetts, by NewsRx correspondents, research stated, "Vitreoretinal lymphoma is a diffuse large B cell non-Hodgkin lymphoma. Targeting malignant cells with rituximab is being used increasingly as local chemotherapy, but information on this treatment is scant."
Our news journalists obtained a quote from the research from Harvard University, "We aimed to describe current therapeutic approaches, as well as responses to and complications of, intravitreal rituximab in patients with vitreoretinal lymphoma. Clinical data were collected in a standardised manner retrospectively on patients with vitreoretinal lymphoma treated with intravitreal rituximab. Results 48 eyes (34 patients) with vitreoretinal lymphoma were treated with a median of 3.5 intravitreal injections of rituximab (1 mg/0.1 mL) for new diagnosis (68.8%), progressive disease (29.9%) and maintenance therapy (2.1%). Intravitreal rituximab +/- methotrexate was the sole treatment in 19 eyes (39.6%). 31 eyes (64.6%) eyes achieved complete remission, after a median of 3 injections; 7 of these eyes developed recurrent disease. 11 eyes (22.9%) achieved partial remission. Although rituximab may have contributed to complications reported in 12 eyes (25.0%), a 2-line loss of Snellen visual acuity occurred in only 2 of those eyes (4.2%)."
According to the news editors, the research concluded: "Approaches in rituximab-based intravitreal chemotherapy vary widely, but our findings suggest that this treatment may be safe and effective in inducing remission in a majority of eyes with vitreoretinal lymphoma."
For more information on this research see: Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. British Journal of Ophthalmology, 2014;98(1):99-103. British Journal of Ophthalmology can be contacted at: Bmj Publishing Group, British Med Assoc House, Tavistock Square, London WC1H 9JR, England. (BMJ Publishing Group - group.bmj.com/; British Journal of Ophthalmology - bjo.bmj.com/)
The news correspondents report that additional information may be obtained from K.L. Larkin, Harvard University, Dept. of Ophthalmol, Cambridge, MA 02138, United States. Additional authors for this research include U.S. Saboo, G.M. Comer, F. Forooghian, F. Mackensen, P. Merrill, H.N. Sen, A. Singh, R.W. Essex, S. Lake, L.L. Lim, D.V. Vasconcelos-Santos, C.S. Foster, D.J. Wilson and J.R. Smith (see also Lymphoproliferative Disorders).
Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Antirheumatics, Biotechnology, Drugs, Oncology, Cambridge, Rituximab, Treatment, Hematology, Chemotherapy, Massachusetts, United States, Medical Devices, Lymphatic Diseases, Lymphoma Gene Therapy, North and Central America, CD20 Monoclonal Antibodies, Tyrosine Kinase Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC